MedTrace Logo

TMS Related Biomarker Assessments

NCT05660018 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-01-09

Study results available
· View outcomes & findings →

Summary

Patients with schizophrenia spectrum disorder (SSD) will be exposed to active and sham repetitive transcranial magnetic stimulation (rTMS) in separate sessions. SSD-related biomarkers will be assessed before and after the rTMS administration.

Conditions

Interventions

DEVICE

active rTMS first, then sham rTMS

Active rTMS is delivered on the first visit, then sham rTMS is delivered on the second visit.

DEVICE

sham rTMS first, then active rTMS

Sham rTMS is delivered on the first visit, then active rTMS is delivered on the second visit.

Sponsors & Collaborators

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Xiaoming Du, PhD · University of Maryland, Baltimore

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-07
Primary Completion
2025-02-14
Completion
2025-02-14
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05660018 on ClinicalTrials.gov